HK1198278A1 - Treatment of multiple sclerosis with combination of laquinimod and interferon beta - Google Patents
Treatment of multiple sclerosis with combination of laquinimod and interferon betaInfo
- Publication number
- HK1198278A1 HK1198278A1 HK14111811.8A HK14111811A HK1198278A1 HK 1198278 A1 HK1198278 A1 HK 1198278A1 HK 14111811 A HK14111811 A HK 14111811A HK 1198278 A1 HK1198278 A1 HK 1198278A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- laquinimod
- treatment
- combination
- multiple sclerosis
- interferon beta
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/21—Interferons [IFN]
- A61K38/215—IFN-beta
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
- A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
- A61J1/14—Details; Accessories therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4704—2-Quinolinones, e.g. carbostyril
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Ophthalmology & Optometry (AREA)
- Psychiatry (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Packages (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161512817P | 2011-07-28 | 2011-07-28 | |
PCT/US2012/048689 WO2013016686A1 (en) | 2011-07-28 | 2012-07-27 | Treatment of multiple sclerosis with combination of laquinimod and interferon-beta |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1198278A1 true HK1198278A1 (en) | 2015-03-27 |
Family
ID=47597382
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK14111811.8A HK1198278A1 (en) | 2011-07-28 | 2014-11-21 | Treatment of multiple sclerosis with combination of laquinimod and interferon beta |
Country Status (16)
Country | Link |
---|---|
US (3) | US20130028866A1 (es) |
EP (1) | EP2736336A4 (es) |
JP (2) | JP2014521659A (es) |
KR (1) | KR20140054129A (es) |
CN (1) | CN103781355A (es) |
AU (2) | AU2012286701A1 (es) |
BR (1) | BR112014002092A2 (es) |
CA (1) | CA2843432A1 (es) |
EA (1) | EA201490378A1 (es) |
HK (1) | HK1198278A1 (es) |
MX (1) | MX2014001048A (es) |
SG (1) | SG10201606204TA (es) |
TW (1) | TW201726137A (es) |
UY (1) | UY34359A (es) |
WO (1) | WO2013016686A1 (es) |
ZA (1) | ZA201401217B (es) |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2682120B1 (en) | 2007-12-20 | 2016-08-03 | Teva Pharmaceutical Industries, Ltd. | Stable laquinimod preparations |
EA201290837A1 (ru) * | 2010-03-03 | 2013-05-30 | Тева Фармасьютикал Индастриз Лтд. | Лечение волчаночного нефрита с применением лаквинимода |
PT2542079E (pt) | 2010-03-03 | 2014-07-18 | Teva Pharma | Tratamento da artrite reumatoide com uma combinação de laquinimod e metotrexato |
KR20140101333A (ko) | 2011-10-12 | 2014-08-19 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드 및 핑골리모드의 조합을 이용한 다발성 경화증의 치료 |
TW201345527A (zh) | 2012-02-03 | 2013-11-16 | Teva Pharma | 拉喹莫德於治療對第一線抗-TNFα療法無效之克隆氏症患者之用途 |
MX2014009889A (es) | 2012-02-16 | 2014-11-13 | Teva Pharma | N-etil-n-fenil-1,2-dihidro-4,5-di-hidroxi-1-metil-2-oxo-3-quinoli ncarboxamida, preparacion y usos de los mismos. |
FR2988058B1 (fr) | 2012-03-15 | 2014-10-03 | A Fermetures As | Dispositif de calage a quai de vehicule de transport de marchandises |
TW201350467A (zh) | 2012-05-08 | 2013-12-16 | Teva Pharma | N-乙基-4-羥基-1-甲基-5-(甲基(2,3,4,5,6-五羥基己基)胺基)-2-側氧-n-苯基-1,2-二氫喹啉-3-甲醯胺 |
TW201400117A (zh) * | 2012-06-05 | 2014-01-01 | Teva Pharma | 使用拉喹莫德治療眼發炎疾病 |
AR091706A1 (es) * | 2012-07-11 | 2015-02-25 | Teva Pharma | Formulaciones de laquinimod sin agentes alcalinizantes |
TW201410244A (zh) | 2012-08-13 | 2014-03-16 | Teva Pharma | 用於治療gaba媒介之疾病之拉喹莫德(laquinimod) |
US8975279B2 (en) | 2012-11-07 | 2015-03-10 | Teva Pharmaceutical Industries, Ltd. | Amine salts of laquinimod |
MX2015010296A (es) * | 2013-02-15 | 2016-05-05 | Teva Pharma | Tratamiento de formas progresivas de esclerosis multiple con laquinimod. |
KR20150143499A (ko) | 2013-03-14 | 2015-12-23 | 테바 파마슈티컬 인더스트리즈 리미티드 | 라퀴니모드 나트륨의 결정 및 이의 개선된 제조방법 |
CA2917600A1 (en) * | 2013-08-01 | 2015-02-05 | Volker KNAPPERTZ | Treatment of multiple sclerosis by alemtuzumab induction followed by laquinimod therapy |
AU2015253330A1 (en) | 2014-04-29 | 2016-12-01 | Teva Pharmaceutical Industries Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status |
EP3303559A1 (en) * | 2015-06-01 | 2018-04-11 | Biogen MA Inc. | Manganese supplementation for control of glycosylation in mammalian cell culture process |
US20190108912A1 (en) * | 2017-10-05 | 2019-04-11 | Iquity, Inc. | Methods for predicting or detecting disease |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6077851A (en) * | 1998-04-27 | 2000-06-20 | Active Biotech Ab | Quinoline derivatives |
WO2007025991A2 (en) * | 2005-09-01 | 2007-03-08 | Ares Trading S.A. | Treatment of optic neuritis |
BRPI0713694A2 (pt) * | 2006-06-12 | 2012-10-30 | Teva Pharma | composição farmacêutica, processo para preparar composição farmacêutica, embalagens vedada, métodos para tratar um indivìduo afligido com uma forma de esclerose múltipla, e para aliviar um sintoma de esclerose múltipla em um indivìduo afligido com uma forma de esclerose múltipla, e, uso da composição farmacêutica |
EP2355660A4 (en) * | 2008-10-13 | 2012-05-02 | Biovista Inc | COMPOSITIONS AND METHODS FOR THE TREATMENT OF MULTIPLE SCLEROSIS |
HUE026406T2 (en) * | 2009-06-19 | 2016-06-28 | Teva Pharma | Treatment of multiple sclerosis with laquinimod |
EP2455080A1 (en) * | 2010-11-23 | 2012-05-23 | Almirall, S.A. | S1P1 receptor agonists for use in the treatment of multiple sclerosis |
AU2015253330A1 (en) * | 2014-04-29 | 2016-12-01 | Teva Pharmaceutical Industries Ltd. | Laquinimod for the treatment of relapsing-remitting multiple sclerosis (RRMS) patients with a high disability status |
-
2012
- 2012-07-27 JP JP2014523093A patent/JP2014521659A/ja not_active Withdrawn
- 2012-07-27 CN CN201280043782.6A patent/CN103781355A/zh active Pending
- 2012-07-27 AU AU2012286701A patent/AU2012286701A1/en not_active Abandoned
- 2012-07-27 EA EA201490378A patent/EA201490378A1/ru unknown
- 2012-07-27 CA CA2843432A patent/CA2843432A1/en not_active Abandoned
- 2012-07-27 BR BR112014002092A patent/BR112014002092A2/pt not_active IP Right Cessation
- 2012-07-27 MX MX2014001048A patent/MX2014001048A/es unknown
- 2012-07-27 KR KR1020147004932A patent/KR20140054129A/ko not_active Application Discontinuation
- 2012-07-27 SG SG10201606204TA patent/SG10201606204TA/en unknown
- 2012-07-27 WO PCT/US2012/048689 patent/WO2013016686A1/en active Application Filing
- 2012-07-27 US US13/560,872 patent/US20130028866A1/en not_active Abandoned
- 2012-07-27 EP EP12817547.8A patent/EP2736336A4/en not_active Withdrawn
- 2012-10-01 UY UY0001034359A patent/UY34359A/es not_active Application Discontinuation
- 2012-10-01 TW TW105134805A patent/TW201726137A/zh unknown
-
2014
- 2014-02-18 ZA ZA2014/01217A patent/ZA201401217B/en unknown
- 2014-10-29 US US14/527,199 patent/US20150056281A1/en not_active Abandoned
- 2014-11-21 HK HK14111811.8A patent/HK1198278A1/xx unknown
-
2016
- 2016-02-22 US US15/050,005 patent/US20160166648A1/en not_active Abandoned
- 2016-07-13 AU AU2016204909A patent/AU2016204909A1/en not_active Abandoned
- 2016-10-26 JP JP2016209185A patent/JP2017061482A/ja not_active Withdrawn
Also Published As
Publication number | Publication date |
---|---|
JP2017061482A (ja) | 2017-03-30 |
MX2014001048A (es) | 2014-07-09 |
US20130028866A1 (en) | 2013-01-31 |
CN103781355A (zh) | 2014-05-07 |
ZA201401217B (en) | 2015-08-26 |
CA2843432A1 (en) | 2013-01-31 |
BR112014002092A2 (pt) | 2017-02-21 |
EA201490378A1 (ru) | 2014-07-30 |
AU2016204909A1 (en) | 2016-08-04 |
NZ621215A (en) | 2015-11-27 |
EP2736336A4 (en) | 2015-03-04 |
UY34359A (es) | 2014-02-28 |
JP2014521659A (ja) | 2014-08-28 |
US20150056281A1 (en) | 2015-02-26 |
WO2013016686A1 (en) | 2013-01-31 |
EP2736336A1 (en) | 2014-06-04 |
US20160166648A1 (en) | 2016-06-16 |
KR20140054129A (ko) | 2014-05-08 |
AU2012286701A1 (en) | 2014-03-06 |
SG10201606204TA (en) | 2016-09-29 |
TW201726137A (zh) | 2017-08-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1198278A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and interferon beta | |
IL251397A0 (en) | Treatment of multiple sclerosis by administering a combination of laquinimod and glatiramer acetate | |
HK1199820A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and fingolimod | |
IL252699A0 (en) | Use of lequinimod to treat multiple sclerosis | |
HK1205941A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and dimethyl fumarate | |
IL252547A0 (en) | Treatment of multiple sclerosis using laquinimod | |
HK1209672A1 (en) | Treatment of multiple sclerosis with combination of laquinimod and fampridine | |
HK1218254A1 (zh) | 用拉喹莫德治療多發性硬化症 | |
HK1206283A1 (en) | Treatment of multiple sclerosis with anti-cd19 antibody -cd19 | |
ZA201408062B (en) | Compositions and methods for the treatment of multiple sclerosis | |
EP2670406A4 (en) | THERAPY COMBINED WITH INTERFERON AND ANDROGRAPHOLIDES FOR MULTIPLE SCLEROSIS | |
HK1223855A1 (zh) | 拉喹莫德和氟吡汀組合物用於治療多發性硬化症 | |
HK1227691A1 (zh) | 利用拉喹莫德和特立氟胺的組合來治療多發性硬化症 |